Stefan Weber, CEO, Newron Pharmaceuticals 00:00:00

Share On Facebook Share On Twitter

Newron Pharmaceuticals is focused on the development of its novel schizophrenia drug with two pivotal Phase III trials due to start in Q221. The company already has a marketed product for Parkinson’s disease

Recent Videos